Navigation Links
Mindray Announces Option Exchange Offer
Date:3/11/2009

SHENZHEN, China, March 11 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced that its Board of Directors has authorized an option exchange program for certain options granted under the Mindray Medical International Limited Share Incentive Plan (the "Share Incentive Plan"). This exchange program, which is only available to eligible employees, is expected to provide additional incentive and retention value.

Under the terms of the exchange, participants will be able to tender vested and unvested outstanding options to purchase Class A ordinary shares of Mindray which have an exercise price greater than $24.00 per share in exchange for a lower number of newly granted options. The exercise price of the new options will be the closing price of Mindray common stock on the New York Stock Exchange on the exchange date. Mindray expects the offer to expire on March 15, 2009 and expects to grant the replacement options on March 16, 2009. The option exchange program is designed so that the current fair value of the options surrendered is similar to the fair value of the replacement options, and any additional expenses due to the exchange offer should be minimal.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" related to our offer to exchange certain stock options for replacement options. These statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Such information speaks only as of the date of this announcement, and we undertake no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About Mindray

Mindray is a leading developer, manufacturer and marketer of medical devices worldwide. Established in 1991, Mindray offers a broad range of products across three primary business segments: patient monitoring & life support products, in-vitro diagnostic products and medical imaging systems. Mindray is globally headquartered in Shenzhen, China, with U.S. headquarters in Mahwah, New Jersey. Mindray also has another 12 international sales and service offices in Amsterdam, Frankfurt, Istanbul, London, Mexico City, Moscow, Mumbai, Paris, Sao Paolo, Seattle, Toronto and Vancouver. For more information, please visit http://www.mindray.com .

    For investor and media inquiries please contact:

    In the U.S:
     Evan Smith, CFA
     FD
     Tel:   +1-212-850-5606
     Email: evan.smith@fd.com

     John Capodanno
     FD
     Tel:   +1-212-850-5705
     Email: john.capodanno@fd.com

    In China:
     May Li
     Mindray Investor Relations
     Tel:   +86-755-2658-2518
     Email: may.li@mindray.com

'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mindray to Report Fourth Quarter and Fiscal Year 2008 Financial Results on March 4, 2009
2. Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009
3. Mindray Announces Preliminary 2008 Operating Results
4. Mindray Medical to Present at the 27th Annual J.P. Morgan Healthcare Conference
5. Mindray Medical to Exhibit at RSNA 2008 in Chicago, from November 30th to December 4th, 2008
6. Mindray Announces 2008 Third Quarter and Nine Months Results
7. Mindray to Report Third Quarter 2008 Financial Results on November 11, 2008
8. Mindray Medical to Exhibit New Products at 60th China International Medical Equipment Fair
9. Mindray Releases Historical Financial Results Converted into US Dollar Terms
10. Mindray to Unveil Three New Products and Reagents at AACC Annual Meeting
11. Mindray Announces 20-F Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... 2017 , ... Girl Up Campaign Director, Melissa Kilby, released ... support of providing girls access to education in refugee settings. In May, Congressman Steve ... Access to Education in Vulnerable Settings Act.” Yesterday, companion legislation was introduced in ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... products that further expand its existing adherence automation lines. The ATP® Mini and ... the advanced technology of TCG’s standard products, but at a size and price ...
(Date:7/20/2017)... ... 20, 2017 , ... With nearly half of all Americans ... company VisitorsCoverage Inc. has launched TMQuotes, a new cloud-based solution platform which gives ... under their own brand. The online marketplace bridges the technological gap in the ...
(Date:7/20/2017)... Henderson, Tennessee (PRWEB) , ... July 19, 2017 ... ... successful second year with a larger audience and increased funds raised to support ... two evening performances of “Disney Aladdin Kids” in Freed-Hardeman University’s Loyd Auditorium. ...
(Date:7/20/2017)... ... July 19, 2017 , ... Med Tech Solutions (MTS), a ... Health IT business unit of Constellation Inc., a move that will help the company ... operations in St. Louis, the acquisition is expected to help MTS expand ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... -- Bayer has awarded grants totaling more than $2 million to ... Bayer Hemophilia Awards Program (BHAP). Four U.S. clinicians and researchers ... and Uniformed Services University of the Health Sciences in ... were announced last night during a reception at the International ... Berlin, Germany . ...
(Date:7/11/2017)...  Sysmex America, Inc., a leading provider of ... well as middleware information systems technology, today announced ... assurance easier and more risk free than manual ... the innovation that it delivers to the laboratory. ... processes to a new level with automated, continuous ...
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( ... development of oral drug delivery systems, announced today that ... to schedule an End-of-Phase II meeting with Oramed for ... insulin capsule ORMD-0801 in the treatment of type 2 ... endpoints by indicating a statistically significant lowering of glucose ...
Breaking Medicine Technology: